Latest News

Novo Nordisk CEO shows new appetite for taking on risk in obesity deals

Mike Doustdar, CEO of Novo Nordisk, was not yet ready to give up on his company's portfolio of obesity drugs.

Doustdar, under pressure to deliver results since taking over the Danish drugmaker's leadership in August, had made five offers that were getting more expensive for Metsera. This is according to U.S. Securities filings and Court documents.

Three sources familiar with the process said that he chose to go ahead and sign a deal worth $10 billion. This is five times more than what Doustdar’s predecessor was willing to pay back in January.

If antitrust regulators had rejected the offer, Novo would have been left without control of Metsera's new obesity drug pipeline. Pfizer was compelled to increase its offer to complete the deal.

Kerry Holford, Berenberg analyst, said Novo's attempts to secure the deal were always going to be difficult.

NEW TOLERANCE FOR RISK

Doustdar was willing to take risks in order to be more competitive than Eli Lilly, according to two sources. This included being more aggressive and faster. Lilly has surpassed Novo in the once dominant position it held on the lucrative U.S. market for weight loss.

Investors and analysts have welcomed the new tone. Erik Berg-Johnsen is the portfolio manager of Storebrand Asset Management's Novo shareholders. He said that the company showed "a clear sense" of urgency to improve its fortunes.

Henrik Hallengreen Laustsen of Jyske Bank, who rates Novo as "buy", said that Doustdar’s decision to acquire Metsera is an "important sign" that it will not be passive.

He said, "They attack the markets rather than have to defend themselves."

Some questioned if Doustdar had gone too far. The bidding battle coincided with increased governance concerns and a shake-up of the board of directors that would give unprecedented control to Doustdar's largest shareholder.

Evan Seigerman of BMO Capital Markets, who rates Novo as a Hold, said that the company still has many other problems to resolve.

You have anticipated pricing headwinds. Lilly is grabbing market share and Novo feels like it has strayed so far from its course that it's difficult to correct.

Holford, a Berenberg analyst, said that Novo must look to acquire deals to boost its drug pipeline, given the relative inaction of mergers and acquisitions in recent years, and looming expirations for patents on semaglutide, an active ingredient found in Wegovy, Ozempic, and other drugs.

Novo has not responded to our request for comment. Metsera declined comment.

NOVO'S CEO WAS CONFIDENT IN FTC'S CERTIFICATION

Doustdar has defended Novo’s pipeline of experimental drugs for weight loss, but stated that an aggressive acquisition strategy is critical to keep pace with a market some analysts estimate will reach $150 billion in the early part of next decade.

The CEO told industry analysts in a recent call that "no pipeline is wide enough" if you want to treat hundreds of millions.

According to securities filings, the final Novo bid structure included higher payments upfront in exchange for 50% of the company, but it delayed the time for gaining control over the business.

Doustdar believed the proposed deal could withstand scrutiny by the U.S. Federal Trade Commission.

It didn't work out as planned. Metsera announced in a press release on November 7, that it had accepted an offer sweetened by Pfizer. The FTC warned Metsera of the antitrust risk associated with the Novo deal. Novo pulled out of this race.

"Every transaction comes with a cost," said Marcus Morris Eyton, portfolio manager at Alliance Bernstein for European and Global Growth Equities. "We are happy to see the management exercise financial discipline when they feel that the price has become too high." (Reporting from Sabrina Valle and Maggie Fick, in New York; Additional reporting by Louise Breusch Rasmussen, in Copenhagen; Editing done by Adam Jourdan and Michele Gershberg; Bill Berkrot).

(source: Reuters)